C-cell hyperplasia

Summary

C-cell hyperplasia (MONDO:0006120) is a disease. A subtype of thyroid gland disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	C-cell hyperplasia
Mondo ID	MONDO:0006120
EFO	EFO:1000147
NCIT	C46100
UMLS	C0342190
MedGen	90975
Is cancer (heuristic)	no

Also known as: C-cell hyperplasia

Disease family

This is a subtype of thyroid gland disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › endocrine system disorder › thyroid gland disorder › C-cell hyperplasia

Related subtypes (11): thyrocalcitonin secretion disease, thyroiditis, hyperthyroidism, thyroid malformation, hyperthyroxinemia, goiter, hypothyroidism, atrophy of thyroid, euthyroid sick syndrome, thyroid tumor, inherited thyroid metabolism disease

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.